WHAT IS MEDICARE PART D?
The Medicare Part D program provides
beneficiaries with assistance paying for prescription drugs. The drug
benefit, added to Medicare by the Medicare Prescription Drug,
Improvement, and Modernization Act of 2003, (MMA),[1]
began in January 2006. Unlike coverage in Medicare Parts A and B, Part D
coverage is not provided within the traditional Medicare program.
Instead, beneficiaries must affirmatively enroll in one of many hundreds
of Part D plans offered by private companies.
The Annual Enrollment Period for Part D runs from November 15 – December
31. During this period people with Medicare can enroll in a plan or
change their enrollment from one plan to another. Individuals who are
already in a plan should decide whether it will be right for them in
the coming year; if they do not choose to
switch they will remain in their current plan.
All plans will have different costs and benefits
from year to year, thus it is advisable for all beneficiaries to
consider their options and make the best choice they can for the coming
year.
While coverage does not begin until January, plans can market beginning
in October and beneficiaries can begin making choices on November
15th.
The
Standard Drug Benefit
The Medicare law establishes a standard Part D drug benefit. Plans must
offer a benefit package that is at least as valuable as the standard
benefit. The standard benefit is defined in terms of the benefit
structure, not the particular drugs that must be covered. In 2008,
this standard benefit includes an initial $275
deductible. After meeting the deductible the beneficiaries pay 25% of
the cost of covered Part D prescription drugs, up to an initial coverage
limit of $2,510. Once the initial coverage
limit is reached, beneficiaries are subject to another deductible, known
as the “Donut Hole,” or “Coverage Gap,” in which they must pay the full
costs of drugs. When total out-of-pocket expenses on formulary drugs
reach $4,050 - including the costs of the
deductible and coinsurance - beneficiaries reach the “Catastrophic
Coverage “ benefit. Beneficiaries entitled to Catastrophic
Coverage pay $2.25 for a generic or preferred
drug and $5.60 for other drugs, or a flat 5%
coinsurance,
whichever is greater.[2]
Note that this out-of-pocket amount is calculated annually.
Beneficiaries who reach the $4,050
out-of-pocket threshold in one year have to begin to meet it again on
January 1st of the next year.
Because the deductible, initial coverage
limit, and annual out-of-pocket threshold change each year according to
the changes in expenditures for Part D drugs, beneficiary out-of-pocket
expenses may increase annually. The Medicare law does not mandate a set
premium amount. These costs as well as the list of covered drugs vary
from plan to plan and from region to region. Beneficiaries should take
time to review the various plans available to them in light of their
current and anticipated needs and financial resources. Decisions
do no have to be made until December 31st.
|
Standard Benefit
2008 |
|
Beneficiary
pays the first $275 (Deductible) |
|
Beneficiary
pays 25% of the next $2,235
(25% of $2,235 = $558.75)
(Initial Benefit Period) |
|
Donut Hole
"Threshold" = $2,510
That is, what
the beneficiary and the plan have spent ($275 + $2,235 =
$2,510) |
|
Beneficiary
pays 100% of the next $3,216.25
(The "Donut
Hole") |
|
"Catastrophic
Coverage" begins after
the beneficiary
has spent $4,050 (this is the total out-of-pocket spending
requirement)
($275 + $558.75 + $3,216.25 =
$4,050)
OR, put another way:
Total spending
(For beneficiary & the plan) for Catastrophic Coverage: $5,726.25
($275 + $2,235
+ $3,216.25 = $5,726.25) |
|
Minimum cost
sharing in Catastrophic Benefit Period: $2.25 (Generic) and
$5.60 (Brand) |
Alternative Coverage and Enhanced Alternative
Coverage
Part
D drug plans are not required to offer the standard benefit, but can offer
alternative prescription drug coverage. Alternative coverage must be
“actuarially equivalent” to the standard benefit. In other words, the
value of the benefit package must be equal to or greater than the value of
the standard benefit package.[3]
In an actuarially equivalent plan the cost-sharing varies through the use of
such mechanisms as tiered co-payments. For example, a beneficiary’s share of
cost may be less for a generic or preferred brand name drug than for a
non-preferred brand name drug. However, a plan that offers an
alternative benefit package cannot impose a higher deductible or require a
higher out-of-pocket limit than required by the standard benefit.
Plans
can offer enhanced alternative coverage that might also include changes to
the deductible and the initial coverage limit, although the deductible
cannot be higher than the amount set in the
statute. Enhanced alternative coverage might also include coverage of
drugs that are excluded under Part D. A PDP that wants to offer a drug
plan with enhanced alternative coverage in a region must also offer a PDP
with the basic benefit package in that region.[4]
Calculating Beneficiary Expenses
Another critical and often over-looked factor is that only the cost of Part
D covered drugs that are included on a plan’s formulary count toward the
deductible and out-of-pocket limits. For example, a beneficiary whose
only drug expenses in 2008
are $400
a month for drugs
that
are not on her plan’s formulary will not meet
her deductible, and the $4800 in out-of-pocket
expenses she will incur for the year will not qualify her for
Part D Catastrophic Coverage.
Payments that count towards the yearly out-of-pocket limit are referred to
as true out of pocket expenses, or TrOOP. Only out-of-pocket costs for
formulary drugs that are paid for by the beneficiary, a family member or
other person acting on her behalf, or by a state pharmacy assistance program
are considered TrOOP and are counted towards the out-of-pocket limit.[5]
Payments made by other insurance, including employer-sponsored plans and
AIDS Drug Assistance Programs (ADAPs), do not count toward the limit.
Such payments work to increase the amount the beneficiary must spend before
the reduced cost sharing for high drug expenses begins. Thus, not only is
the beneficiary responsible for paying the full costs of non-formulary
prescriptions, she gets no credit towards the Part D out-of-pocket limit for
the expenses she incurs.
Covered Part D Drugs
The
MMA defines the drugs that are covered under Part D, and therefore the drugs
for which payment will be made under Part D, in relationship to their
coverage under Medicaid and under other parts of Medicare. A Part D
drug is a drug that is approved by the Food and Drug Administration, for
which a prescription is required, and for which payment is required under
Medicaid.[6]
Biological products, including insulin and insulin supplies, and smoking
cessation drugs are also covered under Part D.[7]
The MMA excludes from coverage those categories of drugs for which Medicaid
payment is optional.[8]
Of particular significance to Medicare beneficiaries is the exclusion of
drugs for weight gain (Used in connection with treating weight loss due to
cancer or HIV/AIDS), barbiturates (Used to treat seizures in older people),
benzodiazepines (Used to treat acute anxiety, panic attacks, seizure
disorders, and muscle spasms in those with cerebral palsy), and over the
counter medications. Many of these excluded medications are used by nursing
home residents.
MMA
also excludes from Part D coverage those drugs for which payment could be
made under Medicare Part A or Part B. CMS has determined that such
drugs are excluded from Part D coverage even if the beneficiary does not
have coverage under the part of Medicare (either Part A or Part B) which
would generally pay for the drug.[9]
Part D Formularies
Part D plans are not required to pay for all covered Part D drugs.
They may establish their own formularies, or list of covered drugs for which
they will make payment, as long as the formulary and benefit structure are
not found by CMS to discourage enrollment by certain Medicare beneficiaries.[10]
Part D plans that follow the formulary classes and categories established by
the United States Pharmacopoeia will pass the first discrimination test.
However, CMS indicates it will still review formularies to determine whether
the placement of specific drugs in each category or class, as well as other
benefit design issues, discriminates against particular individuals.
Importantly, plans can change the drugs on their formulary during the course
of the year with 60 days notice to affected parties.
Exceptions Process
Each
drug plan must develop its own exceptions process under which a plan
enrollee may ask the drug plan to cover a non-formulary drug or to reduce
cost sharing for a formulary drug. In other words, the enrollee asks
the drug plan to make a ruling that formulary requirements apply to all plan
enrollees “except for” the requesting enrollee. An unfavorable exception
determination gets an enrollee into the appeals process. The
prescribing doctor will play an important role in the exception process,
since an exception will only be granted if the plan agrees with the doctor
certification that no other drug on the formulary would be as effective as
the drug in question or formulary drugs would cause adverse consequences to
the enrollee.
The
Center for
Medicare Advocacy, along with The Alzheimer's
Association, American Medical Association, American Pharmacists
Association, Medical Group Management Association, National Community
Pharmacists Association and the National Council on the Aging,
developed a form for pharmacists to fax to physicians when there are
issues with their Medicare patients' prescriptions.
The form has been approved for use by CMS. Click
HERE to download a copy of
the Request for Prescription Information or Change form.
Eligibility for Part D Coverage
Prescription drug coverage under Part D is voluntary. A beneficiary may
purchase Part D coverage if she is entitled to Part A or enrolled under Part
B. The beneficiary does not have to have both Part A and Part B
coverage to choose prescription drug coverage. The beneficiary must
enroll in a Part D plan that serves the geographic region in which she
resides.[11]
Beneficiaries who are incarcerated are not eligible to participate in Part
D.[12]
Choice of Drug Plans
The
Part D benefit is premised on the notion that individual Medicare
beneficiaries should have a choice of private drug plans in order to select
a drug benefit that best meets their needs. The statute creates three
categories of drug plans: stand-alone plans that offer only prescription
drug coverage, Medicare Advantage plans with a drug benefit, and fall-back
plans. (It does not appear that fall-back plans will be needed or
offered in 2007)
Prescription Drug Plans (PDPs)
The
majority of Medicare beneficiaries are in the traditional Medicare program
and will be required to purchase drug coverage through prescription drug
plans (PDPs) that offer only prescription drug coverage. PDPs will be
offered by sponsoring organizations pursuant to a one-year contract with the
Centers for Medicare & Medicaid Services (CMS).[13]
Medicare
Advantage Plans (MA-PDs)
Individuals who are enrolled in a Medicare Advantage plan established under
Medicare Part C must receive their drug coverage through their Medicare
Advantage prescription drug plan, known as an MA-PD. They may not
purchase a separate PDP. However, individuals who are enrolled in a
Medicare Advantage private fee-for-service (PFFS) plan that does not include
a prescription drug option may purchase a PDP for their Part D coverage.[14]
Consequences for People with Low Incomes and for
States
The
MMA establishes a low income subsidy for the costs of Part D. As of January
1, 2006 individuals with incomes up to 150% of the
federal poverty level and with limited resources are eligible for the
subsidy. Unfortunately, the Act also eliminates all Medicaid drug
coverage for the more than six million individuals who are dually-eligible
for both Medicare and Medicaid (dual eligibles). Moreover, it requires
states to pay back to the federal government – through a mechanism referred
to as “the clawback” – much of the savings they would otherwise realize from
the state’s reduced Medicaid obligation, and includes other provisions that
will affect state budgets.
State Pharmaceutical Plans: Medicare Part D
Implications
States may be able to provide cost-sharing and supplemental drug coverage
for dual eligibles and other low-income residents through their State
Pharmaceutical Assistance Program (SPAP).[15]
Any payments made by a SPAP on behalf of a Part D enrollee will count toward
the enrollee’s true out-of-pocket costs, which count toward meeting the
catastrophic threshold which leads to reduced or eliminated enrollee
cost-sharing. State Medicaid programs, including Pharmacy Plus waivers
under Section 1115 of the Social Security Act, ADAPS, and any other programs
where the majority of the funding is from federal programs, cannot be SPAPs.[16]
SPAPs must not discriminate among drug plans with respect to their
supplemental coverage;[17]
this requirement prevents an SPAP from automatically enrolling
subsidy-eligible individuals into one particular drug plan. Plans must
coordinate with SPAPs concerning certain basic elements. For example, a card
issued by a plan may also be used in connection with coverage of benefits
provided under an SPAP, if this is the case, the card may contain an emblem
or symbol indicating such connection.[18].
For CMS'
complete list of qualified SPAPs, go to
http://www.cms.hhs.gov/States/Downloads/QualifiedSPAPList.pdf.
State Medicaid Programs: Medicare Part D Implications
Because of the design of the Medicare drug benefit, many dual eligibles will
find themselves with less prescription drug coverage than they had under
Medicaid and with less protection to challenge denials or other barriers to
coverage. Further, they will have to make co-payments for their
prescriptions, with the co-payment amounts increasing yearly.
Medicaid can continue to cover drugs which are excluded from Part D and are
optionally covered by Medicaid, and receive federal financial participation
(FFP). Such drugs include benzodiazepines, barbiturates, prescription
vitamins, cough and cold relief drugs, and non-prescription drugs, among
others. States also have the option of paying co-payments for dual
eligibles and/or for drugs that are not on a plan’s formulary but will
receive no federal matching payments.
For further information on the
Medicare Modernization Act, you may also refer to our
Medicare Act of 2003 news page and our FAQ - Reform
page. We have also prepared a summary of the new law, available for a
small fee. Click HERE to order.
MEDICARE PART D
LOW-INCOME SUBSIDIES
Full
Subsidy
Medicare Part D will provide
a full drug subsidy with low co-payments to Medicare beneficiaries with
incomes up to 135%
federal poverty level
and limited resources.
Partial Subsidy
Medicare Part D will provide
a partial subsidy of premium, deductible and co-insurance to Medicare
beneficiaries with incomes up to 150%
federal poverty level
and limited (but higher than allowed for full subsidy) resources.
Unlike rules for Medicare
Savings Programs, which allow for a family unit of only one or two,
eligibility rules for Part D subsidies will recognize larger family
units, to the extent that those family members rely on the applicant or her
spouse for one half of their financial support. Because new poverty
guidelines are generally published in February or March of each year, the
prior year's levels will be used to compute Part D
low-income subsidies for the beginning of the next.
2008 LOW
INCOME SUBSIDY GROUPS AND COSTS
|
Standard Benefit |
Group 1
Dual Eligibles |
Group 2
MSP (QMB,
SLMB,QI)
SSI w/o
Medicaid |
Group 3
Income <
135% FPL
Resources
Below $6,000/
$9,000 |
Group 4
Income <
150% FPL
Resources
Below $10.000/
$20,000 |
|
Premium
$25.00/month
(2008) |
$0 up to
"benchmark" |
$0 up to
"benchmark" |
$0 up to
"benchmark" |
Sliding scale
($0 - $25.00)
Based on
income |
|
Deductible
$275
per year |
$0 |
$0 |
$0 |
$50 |
|
Cost Sharing *
up to $4050
out-of-pocket |
co-pays:
$0 if institutionalized
$1.05/$3.10
< 100% FPL
$2.25/$5.60
> 100% FPL |
$2.25/$5.60
co-pay |
$2.25/$5.60
co-pay |
15%
coinsurance |
|
Catastrophic
Coverage
5% or $2.25/$5.60
co-pay |
$0 |
$0 |
$0 |
$2.25/$5.60
co-pay |
* Individuals in these four groups do not have the
“Donut Hole” gap in coverage.
APPLYING
FOR THE LOW INCOME PRESCRIPTION DRUG SUBSIDY
Beginning in May 2005 the
Social Security Administration (SSA) will mail letters to identified low
income Medicare beneficiaries in a series of staggered mailings to inform
them about the Part D Low Income Subsidy (LIS). The LIS is designed to
assist with the cost of the Medicare prescription drug benefit. The
letter will inform beneficiaries that, based on SSA records, they may be
eligible to get extra help paying for their prescription drugs.
SSA and state Medicaid
offices, which are also authorized to take low income subsidy applications,
will evaluate applications using criteria similar to the criteria used to
evaluate applications for Supplemental Security Income (SSI). The
reviewing agency will look at income for both the applicant and the
applicant’s spouse who lives with the applicant, even if the spouse is not
applying for a subsidy. Both unearned and earned income will be
counted, though certain amounts will be disregarded for expenses related to
the individual’s medical condition. As with SSI, the maximum amount of
income counted from in-kind support and maintenance will be one-third of the
monthly benefit rate.
SSA proposes to count
liquid resources, i.e., resources that can be converted to cash within 20
days, in determining whether an applicant for the subsidy meets the assets
test. The home in which a person lives and the land on which it is
situated are excluded from consideration. Again, resources belonging
to a spouse with whom the applicant lives are considered, even if the spouse
is not applying for the subsidy. Other resources excluded from
consideration are non-liquid resources, business or other property necessary
for support, housing assistance, and up to $1500 set aside for burial
expenses.
The proposed regulations do
not set any time limits for SSA to act on a subsidy application; the
application remains in effect until a decision is made. If a subsidy
application is approved, SSA proposes to conduct an eligibility
redetermination within one year of its initial determination. After the
first redetermination, the length of time between redeterminations will vary
depending on SSA’s assessment of the likelihood that a beneficiary’s
situation may change. All redeterminations will be prospective.
If a low-income subsidy
application filed with SSA is denied, or if SSA decides to reduce or
terminate a subsidy, the individual has 60 days to request administrative
review by SSA. (Note: LIS applications filed with the state Medicaid office
are subject to Medicaid agency appeals procedures.) The appeal will
consist of a telephone hearing conducted by someone who was not involved in
making the initial determination. Federal regulations require at least
20 days advance notice of the hearing date, but they do not set a time frame
within which the decision must be made. An individual who is dissatisfied
with the LIS appeal decision has 60 days to file an action in federal
district court seeking review of the decision.
MARK YOUR
CALENDARS! TIMETABLE FOR MEDICARE PART D
ENROLLMENT
August